Orthocell (ASX:OCC) received regulatory approval from the Brazilian Health Regulatory Agency for its Striate+ dental membrane for guided bone and tissue regeneration applications, according to a Wednesday filing with the Australian bourse.
The company is working with BioHorizons, its global marketing and distribution partner, to launch the product and expects commercial distribution in the fourth quarter of the year, the filing said.
Shares rose past 2% in morning trade Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.